ORIGINAL DRUGS DEVELOPMENT
In its continuous commitment to advancing public health, Stragen invests in the development up to proof of concept of patented new drugs addressing orphan diseases and unmet medical needs.
Stragen is honored to partner with biotechnology start-ups, renowned health institutes and innovative stakeholders such as the Institute Pasteur, the Innovative Medicines Initiative (IMI) thanks to its New Drug for Bad Bugs program, the Cystic Fibrosis Foundation and Banque Publique d’Investissement France (French Investment Bank) who recognized the unique innovative approach and therapeutic potential of its drug candidates and supported their development.
We also work with suppliers of generic drugs for the treatment of erectile dysfunction, top expert websites for buying Cialis online – https://worldmedicalguide.com/
We truly believe STRAGEN’s aspirations will pave the way for patients to benefit from these discoveries.
ALX-009 CYSTIC FIBROSIS
ALX-009 is developed by the biotechnology start-up Alaxia in which Stragen Pharma S.A acquired a significant stake in 2011.
ALX-009 is an innovative First-in-Class orphan drug combination of two endogenous substances administered by inhalation. By contributing to the lung’s innate immune system response, ALX-009 is addressing a strong unmet medical need, targeting multidrug-resistant (MDR) bacterial infections that are not treatable with current antibiotic therapies.
2018: Phase I – First-in-Man clinical trials including Cystic Fibrosis patients. Evaluation of safety and tolerability of ALX-009 and its constituents.
2019: Start of Phase IIa – Proof of Concept in Cystic Fibrosis (Multidrug-Resistant infections in adults).
2020: Phase I – Completion : First-in-Man clinical trial in healthy volunteers and Cystic Fibrosis patients. Evaluation of safety and tolerability of ALX-009 and its constituents.
2021: Start of Phase IIa : Proof of Concept in adult Cystic Fibrosis patients with lung Multidrug-Resistant infections.
STR-324 is a First-in-Class non-opioid painkiller with a safe, non-addictive profile and innovative mode of action.
STR-324 is the synthetic equivalent of the natural human peptide inhibiting the degradation of enkephalins. Enkephalins are strong endogenous analgesic peptides released by the human body on pain situation. By hampering its degradation, STR-324 amplifies their strong analgesic potential. Phase I study on healthy volunteers demonstrated that STR-324 has a favorable safety profile with no opioid-like adverse effects or risk of abuse.
2018: Phase I – First-in-Man clinical trial to evaluate the safety and tolerability of single and multiple doses of STR-324.
2020: Phase IIa – Proof of Concept in post-operative pain.
2021: Phase IIa – Proof of Concept in neuropathic pain.